16/3/2015

|ideeaf.gr

...... | 134 &

.: 210 3450753 | Fax: 210 3459324

mail: info@pfs.gr
PFS radio

29 1968 .
.

1993: ( /
) & (),

2002: ()
2013: ( &
, ),

s s ( 1993 2002)
( 2002 2003)
( 2003 2004)
( 2004)
( 1998)
s ( 1998)
( 2000).
(International Headache Society) ( 2003)
(European Neurological Society) ( 2006)

2011-: , 401 .... (2 & 7 )
2004-2011: 401 .... (6 & 6 ).
http://www.ideeaf.gr/eisigites/fakas

1/6

16/3/2015

|ideeaf.gr

2003-2004: 404 ... (1 & 3 ) 20022003: 401 .... (1 & 5 )

2001-2002: 401 .... (3 )
1998-2001: ... . (3 & 9
)
1997: 414 ... (6 )
1996-1997: &
401 .... (9 )
1994-1996: .... & 106 ... (2 )
1993-1994: & 401 .... (1
)

401
, &
(2007 )
&
401 (2004-2011)
401
(2003 & 2004-2011).
(2007 )
- (2004-2007).
401 (2003)
.
(2002-2003)
.
(2002-2003)

. (2002-2003)


1) EXELONTM
1,5 mg (3mg/) 6 mg (12mg/),
,
Alzheimer. (1998-1999), Sub-investigator.
2)Prospective, open, two arm, observer-blind, crossover study to evaluate the efficacy of combination
treatment with Copaxone and Avonex in patients with relapsing-remitting MS: A multicenter study in
Greece HIPPOCRATES-Hellenic Polycentric Post marketing Copaxone-Avonex Trial in
Exacerbating (relapsing) Multiple Sclerosis, as Principal Investigator (2005-2006).
3)A 24-month, double-blind, randomized, multicenter, placebo-controlled, parallel group study
comparing efficacy and safety of FTY720 1.25 mg and 0.5 mg administered orally once daily versus
placebo in patients with relapsing-remitting multiple sclerosis, FREEDOMS (fty720 Research
http://www.ideeaf.gr/eisigites/fakas

2/6

16/3/2015

|ideeaf.gr

Evaluating Effects of Daily Oral therapy in MS), as Principal Investigator (2007-2009).

4) Ph IV, EMR701068_506 , , ,
- ,
-1 (Rebif New Formulation) (
STAR), (2008-2011).
5) Ph IV-COPTIMIZE (MS-GA-401) , , ,

-
(Copaxone),
(2008-2012).
6) Ph III CFTY720D2301E1, EudraCT No 2007-004122-24
, , ,
24 ,
FTY720 1.25 mg 0.5 mg
- , (2009-2010).
7) Ph IV Azilect () 12907
,
(2009-2010).
8) Ph III CFTY720D2399 ,
.5 mg fingolimod (FTY720)
,
(2010-2011).
9) , . CNVF23AGR02
, ,
( -1,
-1, , )

TIMES,
(2010).
10) : Ebixa :
Alzheimer, 13417 (2010-2011).
11) Ph III WA25046, EudraCT 2010-020338-25
, , , -,

, (2011- ).
12) Ph III 105MS301, EudraCT 2008-006333-27
, , -

-1 (017) ,
(2011- ).
13) Ph III 205MS301, EudraCT 2009-012500-11
, -, ,

(DAC HYP - Daclizumab High Yield Process)
Avonex ( -1), -
http://www.ideeaf.gr/eisigites/fakas

3/6

16/3/2015

|ideeaf.gr

, (2011- ).
14) CFTY720DGR02, 29.06.2011

,
(RESPOND), (2011-2012).
15), ,
32

(FTY720) TOFINGO,
(2011-2012).
16) Ph IV CNVF233AGR03/15-6-2011
,
,
Extavia ( -1) FIGHT,
(2011-2013).
17), , ,
() , (2011-2012).
18) , ,
Rebif ,
, , 035 (2011-2012).
19) Ph IV ,

Gilenya (). DIAMOND, (2012- ).
20) ,
EFC6058, EudraCT 2010-023172-12
-,

-, TERACLES,
(2012- 2013).
21) () ,
Natalizumab (Tysabri), TOPICS GRC 2011,
(2012- ).
22) Ph III GA-MS-302/ GLOW , ,
, , ,
- , ,
20 mg/0,5 ml,
, (2012- ).
23)
RebiSmartTM
: GEPAT-SMART (2013- ).
24)
- Betaferon
COGNIPLUS (2013- ).
25) Gilenya ,
CFTY720D2404 (2013- ).
http://www.ideeaf.gr/eisigites/fakas

4/6

16/3/2015

|ideeaf.gr

26) , -, , ,

Alzheimer, 09004 (2013- ).
27) , , , , ,
,
,
(0,6 mg/ 1,2 mg/) -
(RRMS, LAQ-MS-305 (2013- ).
28) , , -,
, 96 , ,
4.5 mg/Kg/

, 07002 (2013- ).
29) 2/3, , , ,
( ) , ,
( ),
RPC1063
, RPC01-201 (2013- ).

& : : 56 (: 12 & : 44).
, 1 : 16 (: 3 & : 13)
42 , , ,
.
investigator meetings on multiple sclerosis: (7)
advisory board meetings on multiple sclerosis: (3)
: (6)
: (3)

Webinars
20/11/2013

27/11/2013
:

&
" "

http://www.ideeaf.gr/eisigites/fakas

5/6

16/3/2015

|ideeaf.gr

11.3.2015 11 webinar

4.3.2015 10

Copyright 2011 - 2012 ...... - &

http://www.ideeaf.gr/eisigites/fakas

6/6